23andMe (NASDAQ:ME) Announces Quarterly Earnings Results

23andMe (NASDAQ:ME) announced its earnings results on Thursday. The company reported ($0.12) EPS for the quarter, reports. The firm had revenue of $64.03 million for the quarter, compared to analyst estimates of $61.90 million. 23andMe had a negative net margin of 303.55% and a negative return on equity of 55.18%.

23andMe Stock Performance

NASDAQ:ME opened at $0.51 on Friday. The company has a fifty day simple moving average of $0.49 and a two-hundred day simple moving average of $0.67. 23andMe has a 52 week low of $0.35 and a 52 week high of $2.15.

Wall Street Analyst Weigh In

Separately, Citigroup decreased their price objective on 23andMe from $0.85 to $0.47 and set a “neutral” rating on the stock in a report on Tuesday, April 16th.

Institutional Investors Weigh In On 23andMe

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of 23andMe by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 28,145,216 shares of the company’s stock worth $27,518,000 after acquiring an additional 834,504 shares in the last quarter. Wittenberg Investment Management Inc. raised its holdings in 23andMe by 63.9% during the first quarter. Wittenberg Investment Management Inc. now owns 2,290,945 shares of the company’s stock worth $1,219,000 after purchasing an additional 893,552 shares in the last quarter. Swiss National Bank boosted its holdings in shares of 23andMe by 2.5% in the 3rd quarter. Swiss National Bank now owns 579,800 shares of the company’s stock valued at $567,000 after buying an additional 14,000 shares in the last quarter. Commonwealth Equity Services LLC boosted its holdings in shares of 23andMe by 4.6% in the 3rd quarter. Commonwealth Equity Services LLC now owns 370,934 shares of the company’s stock valued at $363,000 after buying an additional 16,390 shares in the last quarter. Finally, Mirador Capital Partners LP grew its position in shares of 23andMe by 11.2% in the 1st quarter. Mirador Capital Partners LP now owns 340,946 shares of the company’s stock valued at $181,000 after buying an additional 34,321 shares during the last quarter. Hedge funds and other institutional investors own 36.10% of the company’s stock.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.